Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.07 -0.03 (-2.73%) Market Cap: 273.45 Mil Enterprise Value: 161.16 Mil PE Ratio: 0 PB Ratio: 10.70 GF Score: 70/100

Q3 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript

Nov 08, 2022 / 01:00PM GMT
Release Date Price: $2.08 (+25.30%)
Operator

Hello, and welcome to Adaptimmune's Third Quarter Call and Business Update. I will now turn the call over to Juli Miller. Juli, Please go ahead.

Juli P. Miller
Adaptimmune Therapeutics plc - VP of IR

Good morning, and welcome to Adaptimmune's conference call to discuss our third quarter 2022 financial results and business update. I would ask you to review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC.

Adrian Rawcliffe, our Chief Executive Officer, is here with me for the prepared portion of the call. Other members of our management team will be available for Q&A.

With that, I'll turn the call over to Adrian Rawcliffe. Adrian?

Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director

Thank you, Juli, and thank you for joining us today. As

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot